Scratch assay performed by Dr. Miller with adipose-derived stem cells (hASCs). 250K hASCs can be acquired from one gram of aspirated fat tissue in biopsy or liposuction procedures. Accelerated growth displayed versus the control.
RPE monolayer at 4x - cells grown over 100 days.
This cell type uses phagocytosis to engulf rods and cones after damaged taken by UV. Understanding how this applies to astronauts is key for long-term presence in space.
Our cannabinoid approach aims to develop new drug therapies or understand better how the endocannabinoid pathway of the prefrontal cortex operates under varying conditions.
Our gene therapy approach aims to develop new drug therapies or even correct genetic defects by delivering therapeutic genes to the affected cells, potentially curing a wide range of inherited diseases.
Lenti viral therapies are of growing interst in CarT therapies. We aim to provide support to target and treat a range of diseases, including cancer, neurological disorders, and more.
Our regenerative medicine solutions use stem cells and other advanced techniques to repair and replace damaged tissues, potentially providing advantages previously unavailable.
Our bioengineering expertise enables us to create novel biomaterials, implants, and other medical devices, improving patient outcomes and quality of life.
Deep Space Therapeutics
Copyright © 2024 Deep Space Therapeutics - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.